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Abstract
Pancreatic ductal adenocarcinoma (PDAC) and other carcinomas are hierarchically organized, 
with cancer stem cells (CSC) residing at the top of the hierarchy, where they drive tumor 
progression, metastasis, and chemoresistance. As CSC and non-CSC share an identical genetic 
background, we hypothesize that differences in epigenetics account for the striking functional 
differences between these two cell populations. Epigenetic mechanisms, such as DNA 
methylation, play an important role in maintaining pluripotency and regulating the differentiation 
of stem cells, but the role of DNA methylation in pancreatic CSC is obscure. In this study, we 
investigated the genome-wide DNA methylation profile of PDAC CSC, and we determined the 
importance of DNA methyltransferases for CSC maintenance and tumorigenicity. Using high-
throughput methylation analysis, we discovered that sorted CSCs have a higher level of DNA 
methylation, regardless of the heterogeneity or polyclonality of the CSC populations present in the 
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tumors analyzed. Mechanistically, CSC expressed higher DNMT1 levels than non-CSC. 
Pharmacologic or genetic targeting of DNMT1 in CSCs reduced their self-renewal and in vivo 
tumorigenic potential, defining DNMT1 as a candidate CSC therapeutic target. The inhibitory 
effect we observed was mediated in part through epigenetic reactivation of previously silenced 
miRNAs, in particular the miR-17-92 cluster. Together, our findings indicate that DNA 
methylation plays an important role in CSC biology and also provide a rationale to develop 
epigenetic modulators to target CSC plasticity and improve the poor outcome of PDAC patients.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents the fourth most frequent cause of 
cancer-related death due to its extreme lethality and current lack of effective treatments (1). 
As incidence and death rates continue to increase, pancreatic cancer is predicted to become 
the second most frequent cause of cancer-related death by 2030 (2), making this disease a 
major unmet priority in public health care. Although multiple subclonal populations of 
cancer cells coexist within each tumor and are assumed to drive tumor adaptation and 
therapeutic failure through Darwinian selection (3), convincing evidence now demonstrates 
that cancer heterogeneity is also driven by phenotypic and functional heterogeneity within 
each of these subclones, resulting in a hierarchical tumor organization (4). At the apex of 
this hierarchy are populations of cancer stem cells (CSC) capable of self-renewal and long-
term in vivo tumorigenicity. CSCs give rise to more differentiated progenies (non-CSCs), 
which, although sharing common mutation profiles, bear distinct and thus most likely 
epigenetically defined gene expression patterns (5, 6).
Identifying the epigenetic mechanisms that are responsible for the acquisition and 
preservation of these distinct CSC features could open up possibilities for the development 
of new and more effective therapeutic strategies for PDAC. Unlike genetic mutations, 
epigenetic changes are transient and reversible, and as such, therapies that convert the 
epigenetic balance of CSCs toward that of non-CSCs could provide the basis for developing 
more effective treatment strategies for cancer patients (7). Among the first epigenetic drugs 
proposed were inhibitors of DNA methylation, for example, 5-azacytidine (5-aza-CR, 
azacytidine) and 5-aza-2′-deoxycytidine (5-aza-CdR, decitabine), followed later by 
zebularine, which all incorporate into DNA and form covalent irreversible complexes with 
DNA methyltransferases (DNMT; ref. 8). These inhibitors have been shown to induce 
differentiation of cultured cancer cells (9), but our knowledge about their effects on CSCs is 
still sparse. Moreover, to date, only few studies have utilized the new DNA methylation 
inhibitor zebularine, which can be administered orally and is less toxic (10). Thus, we aimed 
to characterize the supposedly distinct methylation profile of primary pancreatic CSCs and 
subsequently studied the effects of genetic or pharmacologic targeting of DNMT1 on CSC 
phenotypes.
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Materials and Methods
Primary human cancer cells
PDAC tumors were obtained with written consent from all pancreatic cancer patients, 
expanded in immunocompromised mice as patient-derived xenografts (PDX), and 
subsequently digested to establish low-passage primary cell cultures (11).
In vivo tumorigenicity
Serial dilutions of primary pancreatic cancer cells were resuspended in Matrigel (BD 
Biosciences), subcutaneously injected into the right and left flank of female NU-Foxn1nu 
nude mice (Harlan Laboratories), and tracked for up to 3 months. Experiments were 
approved by the Animal Experimental Ethics Committee of the Instituto de Salud Carlos III 
(Madrid, Spain; CBA 68_2013 & CBA 25_2009) and performed in accordance with the 
guidelines for Ethical Conduct in the Care and Use of Animals. CSC frequency was 
calculated using the extreme limiting dilution analysis (LDA) algorithm (http://
bioinfo.wehi.edu.au/software/elda/index.html).
Sphere formation assay
Spheres were generated by culturing 2 × 103 PDAC cells/mL in ultra-low attachment plates 
(Corning) using serum-free DMEM/F12 supplemented with B27 (1:50, Invitrogen), 20 
ng/mL bFGF, and 50 U/mL penicillin/streptomycin for 7 days. For serial passaging, sphere 
cultures were depleted for single cells and "spheres" measuring <40 μm using a 40-μm cell 
strainer. Retained spheres were dissociated into single cells, recultured for another 7 days. 
Spheres >40 μm were quantified with a CASY Cell Counter (Roche; ref. 11). Primary 
sphere-derived human PDAC cells were treated with zebularine (75 μmol/L) or decitabine 
(50 μmol/L) for 7days. The drugs were readministered every other day to the cell 
suspension.
Flow cytometry analysis and FACS
Primary pancreatic cells, dissociated spheres, or cells from tumor digestions were stained 
with anti-hCD133/1-APC or PE (Miltenyi Biotec), hEPCAM-APC (Miltenyi Biotec), 
hCD324-APC (BioLegend), hPan-Cytokeratin-FITC (Miltenyi Biotec), or appropriate 
control antibodies (all from BD Biosciences), counterstained with DAPI (2 μg/mL) for 
exclusion of dead cells, and analyzed using a FACSCanto II instrument (BD Biosciences). 
Data were analyzed with FlowJo 9.2 software (Tree Star). For FACS analysis, cells were 
adjusted to a concentration of 106 cells/mL in sorting buffer [1× PBS; 3% FBS (v/v); 3 
mmol/L EDTA]. DAPI was added to exclude dead cells, and cells were sorted using a FACS 
Influx instrument (BD Biosciences).
DNA methylation analysis
Genomic DNA (1 μg) was treated by bisulfite conversion with the EZ DNA Methylation Kit 
(D5004, Zymo Research) according to the manufacturer's recommendations. The 
HumanMethylation450K BeadChip (Illumina, Inc.) was used for analysis of genome-wide 
DNA methylation according to the manufacturer's instructions. To identify differently 
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methylated probes in paired autofluorescent-positive and -negative cells from all tumors, we 
used limma package (12). Probes were considered to be differentially methylated if the 
resulting adjusted P value was <0.05. The Benjamini–Hochberg method was used to adjust 
the P values and ensure that the FDR was <0.05. The genomic regions of the probes from 
the array were assigned according to their position relative to the transcript information 
obtained from the R/Bioconductor package FDb.InfiniumMethylation.hg19 (R package 
version 2.9.2). The CGI locations used in the analyses were obtained from the R/
Bioconductor package FDb.InfiniumMethylation.hg19 (R package version 1.0.1). The 
definition of CGI was done as described previously (13).
Statistical analysis
Results for continuous variables are presented as means ± SEM unless stated otherwise, and 
significance was determined using the Mann–Whitney U test. All analyses were performed 
using SPSS 22.0 (SPSS). Significance was considered at P < 0.05.
Additional experimental details can be found in the Supplementary Materials and Methods.
Results
Pancreatic CSCs bear higher DNA methylation levels
We first performed genome-wide comprehensive methylation profiling using the 450K 
Illumina bead array (14) to gain insight into putative DNA methylation differences between 
CSCs and non-CSCs. CSCs can be separated from the tumor bulk population by several 
methods (11); however, we recently showed that PDAC CSCs can also be efficiently isolated 
using autofluorescence (an accumulation of riboflavin in ATP-dependent transporter 
ABCG2-coated vesicles exclusively found in CSCs; ref. 15). Using this CSC inherent 
marker, we separated CSCs from non-CSCs by FACS sorting (Fig. 1A; ref. 15), and the 
efficient enrichment for CSCs was validated by increased expression of pluripotency-
associated genes in autofluorescent-positive (Fluo+) CSCs versus Fluo− cells 
(Supplementary Fig. S1A and S1B).
As the vast intratumoral heterogeneity in PDAC might obscure distinct methylation profiles 
between CSCs and non-CSCs within each contained subclone, we did not only use cells 
derived from a heterogeneous primary pancreatic tumor (PDAC-185), but also analyzed a 
liver metastasis (PDAC-A6L) and a single cell–derived (SCD) tumor that was generated 
using a single CSC isolated from the primary tumor (PDAC-185 SCD; Supplementary Fig. 
S1C and S1D). We reasoned that the CSC heterogeneity should be highest in the primary 
tumor, less in the metastatic tumor, and homogenous in the CSCs isolated from the SCD 
tumor. DNA methylation levels were compared between CSCs and non-CSCs for each 
individual tumor, which revealed a slight, but significant increase in DNA methylation in the 
Fluo+ CSC compartment, regardless of the heterogeneity or polyclonality of the CSC 
populations present (Fig. 1B). These data suggest consistent differences in the methylation 
profile despite considerable intratumoral heterogeneity.
Furthermore, we looked at differentially methylated probes (hyper- or hypomethylated) in 
CSCs and found that their distribution was not universal. Hypermethylation was mostly 
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located in non-CGI (OD = 1.43) and intergenic regions (OR = 1.17), and hypomethylation 
was mostly found in CGI (OR = 1.80) and promoter regions (OR = 1.43; Fig. 1C), indicating 
that the hypermethylation phenotype observed in the pancreatic CSC population is largely a 
result of methylation of regions that are outside of traditional CGI. To further confirm this 
observation, we measured the levels of the DNA methylation mark 5-methylcytosine (5 mC) 
using the MethylFlash Methylated DNA Kit or by manual dotblot analysis and show that 
regardless of the method used to isolate CSCs (sphere vs. adherent, Fluo+ vs. Fluo- or 
CD133+ vs. CD133-), the CSC population exhibited consistently higher levels of 5 mC, 
indicating that cytosine was methylated to 5-methylcytosine by DNMTs, which is in line 
with our Illumina Array data (Fig. 1D and Supplementary Fig. S2A).
Pancreatic CSCs overexpress DNMT1
We next asked whether hypermethylation could be explained by differential expression of 
DNMTs. Most strikingly, we found higher mRNA expression levels of DNMT1 in the CSC 
population, regardless of the isolation method used (Fig. 2A and C and Supplementary Fig. 
S2B). Western blot analysis confirmed higher DNMT1 protein expression in CSCs versus 
non-CSCs (Fig. 2B–D). On the basis of the above data, we reasoned that DNMT1 
overexpression plays a decisive role in preserving the stemness state of CSCs via 
maintaining their distinct methylation state (16).
DNMT1 inhibition decreases PDAC CSCs phenotypes
On the basis of the aforementioned results, we aimed to pharmacologically target DNMT1 
using zebularine to reverse the distinct methylome signature of CSCs and assess whether 
DNMT1 inhibition could ablate PDAC CSC tumorigenicity. Three primary PDAC cell 
cultures were treated with zebularine over the course of 7 days in conditions that enrich for 
CSCs (Supplementary Fig. S3A and S3B). A concentration of 75 μmol/L was used in all of 
our subsequent experiments as cytotoxicity studies revealed that concentrations ≥100 μmol/L 
were potentially toxic (Supplementary Fig. S3C).
Although zebularine expectedly showed minor or no effect on DNMT1 mRNA levels 
(Supplementary Fig. S3D), we observed a consistent inhibition of DNMT1 at the protein 
level (Fig. 3A) and a marked reduction in CD133 mRNA and surface protein levels (Fig. 
3B), suggesting preferential targeting of CSCs. A similar reduction was observed when we 
sorted cells for autofluorescence to identify CSCs (Supplementary Fig. S3E). At the 
functional level, zebularine reduced both CSC self-renewal in vitro (Fig. 3C) and the 
expression of pluripotency-associated genes (Fig. 3D). To further corroborate that 
pharmacologic inhibition of DNMT1 is suitable for targeting pancreatic CSCs, we used 
another DNMT inhibitor, decitabine. Indeed, nontoxic levels of DAC (Supplementary Fig. 
S4A) decreased DNMT1 protein levels (Supplementary Fig. S4B) and subsequently reduced 
the self-renewal capacity of CSCs in three different PDAC cultures (Supplementary Fig. 
S4C). Moreover, decitabine treatment significantly decreased the expression of the 
pluripotency-associated gene OCT3/4 (Supplementary Fig. S4D). The differential effects on 
the expression of pluripotency-associated genes between zebularine and decitabine may, at 
least in part, be related to differences in DNA-hypomethylating properties of the drugs as 
previously suggested (17). Nonetheless, at the functional level, both DNMT1 inhibitors 
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significantly inhibited the CSC population. As the most defining feature of CSCs is their 
ability to form tumors in vivo, we also performed limiting dilution in vivo tumorigenicity 
assays with control or Zebularine-treated cells to assess their tumorigenic potential. 
Zebularine-treated cells produced significantly fewer (and smaller) tumors, resulting in a 5- 
to 6-fold lower calculated CSC frequency (Fig. 3E, left). Moreover, in tumors that did form, 
the percentage of CD133+ cells was markedly reduced (Fig. 3E, right), already suggesting 
enhanced epithelial differentiation as a possible mechanism of action.
Knockout of DNMT1 decreases CSCs phenotypes
DNMT1 inhibitors, including zebularine and decitabine, have a similar mode of action 
(incorporation into DNA as cytosine analogues). The formation of covalent adducts between 
DNA and trapped DNA methyltransferase protein can induce toxic effects, making it 
difficult to separate demethylating activity from cytotoxicity (18). Therefore, to genetically 
verify our hypothesis that DNMT1 is indeed crucial for maintaining the CSC status, we 
generated PDAC cells lacking DNMT1 via CRISPR/Cas9 editing. After two weeks under 
selection, the 185 DNMT1-KO cells showed complete loss of DNMT1 expression at the 
protein level (Fig. 4A). The subsequent loss of DNMT1 (i) decreased the percentage of 
CD133+ CSCs (Fig. 4B), (ii) significantly abrogated the in vitro self-renewal capacity of 
CSCs as measured by multiple generation sphere formation potential (Fig. 4C), and (iii) 
decreased the expression of pluripotency-associated genes (Fig. 4D).
The DNMT1 inhibition promotes CSC proliferation and differentiation
The effects of DNMT1 inhibition on CSCs may be related to (i) apoptosis induction, (ii) 
cell-cycle arrest, or (iii) promotion of differentiation. Zebularine treatment during sphere 
formation did not significantly alter the percentage of early or late apoptotic cells in the 
entire tumor cell population (Fig. 5A, left) nor was there any evidence of apoptosis induction 
specifically in the CD133+ CSC population (Fig. 5A, right). Cell-cycle analysis, however, 
revealed reduced numbers of zebularine-treated cells residing in G0 and an increased number 
of actively cycling cells (Fig. 5B). Moreover, not only did we observe a decrease in the 
percentage of CD133+ CSCs upon treatment (Fig. 3B), but by comparing ratios between the 
CD133− and the CD133+ cell populations, we found that the decrease in CD133+ CSCs was 
followed by an increase in their CD133− non-CSC counterparts, suggesting that zebularine 
treatment potentially induced the "differentiation" of CSCs to non-CSC (Fig. 5C). This 
result was confirmed by assessing the cell surface levels of pan-cytokeratin and E-cadherin 
(Fig. 5D and E and Supplementary Fig. S5A and S5B) as markers of more differentiated 
PDAC cells (6). Higher expression of pan-cytokeratin and E-cadherin could also be observed 
following decitabine treatment (Supplementary Fig. S4E) and DNMT1 knockout 
(Supplementary Fig. S5C). Together, our data suggest a quiescence-inhibiting and 
differentiation-promoting effect of DNMT1 inhibition on pancreatic CSCs.
DNMT1 inhibition affects CSCs via hypomethylation of the miR-17-92 cluster
To determine the molecular mechanism(s) responsible for the effect of zebularine on CSCs, 
we analyzed putative changes in DNA methylation using the Illumina Infinium 
HumanMethylation450 Bead Chip. As expected, zebularine treatment decreased DNA 
methylation in PDAC CSCs (Fig. 6A). Interestingly, while methylation of many genes was 
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changed upon treatment, others even gained methylation. Using a stringent analysis 
approach (fold change in β-methylation values less than 0.5 and fold change higher than 2), 
we found 97 and 548 genes demethylated and methylated, respectively (Supplementary 
Tables S1 and S2). While these genes are currently under investigation, previous work by 
our group indicated that miRNAs have an important role in PDAC CSCs, and thus, we 
initially focused our analysis on modulated miRNAs. Indeed, as shown in Table 1, we 
identified several miRNA more methylated in CSC-enriched spheres versus non-CSC 
adherent cultures, and using a less stringent analysis (fold change in β-methylation values 
0.8), many were subsequently hypomethylated following zebularine treatment 
(Supplementary Table S3).
Among these, we identified miR-203 and -205, which have previously been implicated in 
promoting cellular differentiation (19). Although the expression of these miRNAs could not 
be confirmed to be significantly altered by zebularine (Supplementary Fig. S6A), we did see 
a strong and significant increase in the expression of these two miRNAs in DNMT1-KO 
cells (Supplementary Fig. S6B). Next, we focused our attention on the miR-17HG 
(miR-17-92 cluster host gene) as a potentially methylation-regulated miRNA as zebularine 
treatment phenocopied previous data from our laboratory related to the miR-17-92 cluster in 
CSCs (20). We previously showed that suppression of this cluster was necessary for the 
maintenance of CSC phenotypes and artificial overexpression of miR-17-92 members forces 
quiescent CSCs into an active cell-cycle state (20). Likewise, previous reports have observed 
a CpG island in close proximity of the miR-17-92 promoter (21). Encouraged by these 
findings, we further investigate whether hypermethylation of this CpG island could be 
responsible for the apparent suppression of this important miRNA cluster in CSC-enriched 
spheres (20). Indeed, analysis of our methylation array data showed that CpG sites in close 
proximity of the miR-17-92 cluster were hypomethylated upon zebularine treatment 
(Supplementary Table S3). Using an independent set of CSC-enriched samples from various 
PDAC tumors, we observed a consistent and notable increase in the expression of several 
miR-17-92 members following zebularine treatment (Fig. 6B), with a particular increase in 
miR-19a and miR-19b. Consistently, the increased expression of miR-17-92 members, in 
particular miR-19b, was mimicked in cells lacking DNMT1 (Supplementary Fig. S6C). Of 
note, miR-92a, bearing a unique seed sequence distinguishing it from the other miR-17-92 
family members, was not modulated by zebularine treatment (control vs. zebularine: 1.13 
± 0.02-fold change, n.s.). Known targets of the miR-17-92 cluster, such as P21 (CDKN1A), 
TGFBR2, ACVR1B (ALK4), SMAD2, and SMAD4, have also been implicated in 
pancreatic CSC phenotypes including self-renewal and chemoresistance (11, 20). We found 
that many of these genes were suppressed upon zebularine treatment at both the mRNA (Fig. 
6C) and protein levels (e.g., P21; Fig. 6D), recapitulating our previous findings (20) and 
suggesting that DNMT1 inhibition is capable of unlocking the epigenetic repression of this 
cluster in CSCs to reactivate repressed "anti-CSC" miRs.
It has been shown that the MYC proto-oncogene family is also involved in the 
transcriptional regulation of miR-17-92 (22). MYC is generally overexpressed in PDAC, but 
we recently showed that MYC is actually suppressed in pancreatic CSCs (23), which may 
contribute to the specific reduced expression of the miR-17-92 cluster in these cells. Indeed, 
our methylation array data indicated that CpG sites annotated to MYC were more 
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methylated in CSCs (fold change adherent vs. sphere: 1.57 ± 0.18), which could be reversed 
by zebularine treatment (fold change control vs. zebularine: 0.80 ± 0.02). We consistently 
found a significant increase in c-MYC mRNA levels in CSC-enriched spheres upon 
treatment with zebularine (Fig. 6E).
Finally, to provide more conclusive evidence that the effects of DNMT1 inhibition were 
primarily mediated via reactivation of the miR-17-92 cluster, we performed loss-of-function 
experiments in the presence or absence of zebularine. For this purpose, we plated primary 
PDAC cells in adherent conditions to obtain a predominantly differentiated PDAC culture 
and treated these cells for 24 hours with antagomiR targeting the various members of the 
miR-17-92 cluster to promote "stemness," as described previously (20). Following 
antagomiR treatment, we next plated the cells in ultra-low adhesion conditions (sphere 
culture) to foster the expansion of CSCs and then treated cultures with zebularine to 
competitively reverse the effects on CSC phenotypes mediated via miRNA downregulation. 
Zebularine reversed the antagomiR-mediated enhancement of sphere formation (Fig. 6F), 
supporting the conclusion that zebularine mediates its inhibitory effects on CSCs, at least in 
part, by inducing the expression of the members of the miR-17-92 cluster, which functions 
to repress the expression of CSC-promoting genes.
Discussion
Recent advances in our understanding of CSC epigenetics provide important insights into 
how these cells acquire their specific stem-like characteristics and, at the same time, shed 
light on how CSCs can be successfully targeted using epigenetic-modifying agents (24). Our 
data demonstrate that pancreatic CSCs (i) bear higher DNA methylation levels, (ii) express 
high levels of the DNMT methyltransferase protein DNMT1 and (iii) loose stemness upon 
pharmacologic or genetic inhibition of DNMT1. Although previous studies have already 
shown that DNMTs are overexpressed in other cancer tissues compared with normal tissue 
(25, 26), herein we report specific upregulation of DNMT1 in PDAC and provide data to 
support its role as an important epigenetic modifier in pancreatic CSCs. Intriguingly, 
demethylation of pancreatic CSCs using the DNMT1 inhibitors zebularine and decitabine 
markedly reduced their CSC functions and properties, an effect that was regulated via 
DNMT1-mediated demethylation of the miR-17-92 cluster promoter. These data are in line 
with reports for other cancers where DNMT1 was also found to be essential for the 
maintenance of stem cells (27, 28), but we now also provide a mechanistic link in the 
context of PDAC by demonstrating the modulation of a crucial miRNA cluster.
Epigenetic modifications are able to alter gene expression and have been shown to play a 
crucial role in stem cell function and maintenance (27, 29). As CSCs and their more 
differentiated progenies share the same genetic background, epigenetic changes should 
account for the striking functional differences between CSCs and their nontumorigenic 
progenies. Specifically, we recently demonstrated that even a single CSC could give rise to a 
tumor that recapitulated the functional heterogeneity of the original parental tumor at the 
pathologic, biologic, and genetic levels (15). Thus, epigenetics and not genetics must be the 
underlying drivers of this intraclonal heterogeneity, which is indeed supported by our present 
finding that the genome of CSCs is hypermethylated compared with non-CSCs. Strikingly, 
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DNA hypermethylation could not only be found in single-CSC-derived tumors that lack 
intratumoral heterogeneity, but also in tumors derived from metastatic lesions and even 
highly heterogeneous primary tumors. This finding supports the notion that 
hypermethylation is a consistent and robust differential factor between pancreatic CSCs and 
non-CSCs. At the DNA level, this hypermethylation phenotype was restricted to regions 
outside traditional CpG islands, specifically non-CpG islands and intergenic regions. In 
general, it has been shown that cancer cells exhibit hypomethylation of intergenic regions 
(30), which consequently could contribute to activation of transposable elements and 
genome instability. On the other hand, promoter regions of many CpG islands of tumor 
suppressor genes become hypermethylated, resulting in their loss of function (31). 
Fortunately, using genome-scale methylation screening approaches, we have learned that a 
fraction of normally methylated CpG islands become hypomethylated and transcriptionally 
active in cancer cells (32). Moreover, some CpG islands located within the 3′ ends of genes 
(33) and in intergenic regions (34) exhibit hypermethylation in cancer cells. It is still unclear 
to what extent methylation of these nonpromoter CpG islands might affect gene expression 
and more importantly what is the subsequent result/phenotype in different populations of 
cancer cells. Although further studies are necessary to address these specific questions in the 
context of CSCs, our data allude to a possible mechanism by which PDAC CSCs may 
protect their genome from undesirable transcription or instability, achieving better fitness for 
survival and growth than their more differentiated non-CSC counterparts.
DNA methylation is evolutionarily ancient and associated with gene silencing in eukaryotes. 
It represents a key regulatory mechanism for the self-renewal and differentiation programs 
of embryonic stem cells and of adult stem cells (35). Maintenance of their "stemness" state 
is conferred to the set of developmental transcription factors (OCT4, NANOG, and SOX2), 
occupying promoters of genes associated with self-renewal. Expression of these 
transcriptional regulators is usually controlled by CpG promoter methylation, and 
differentiation is accomplished by partial or full methylation of pluripotency-associated 
genes, resulting in their downregulation (36). Thus, it is conceivable to predict that treatment 
of CSCs with demethylating agents would further upregulate pluripotency-associated gene 
expression; however, we observed a downregulation of pluripotency factors, indicating that 
the epigenetic wiring of CSCs is not only different than stem cells but that other epigenetic 
regulators are likely shaping the epigenetic landscape of CSCs.
Zebularine, a cytidine analogue, acts primarily as a trap for DNMT proteins by forming tight 
covalent complexes between DNMT proteins and DNA after zebularine incorporation (10). 
It is believed that the antitumor effects of DNMT inhibitors, such as zebularine or 
decitabine, are largely due to the reexpression of tumor suppressor genes (37), which are 
often silenced in cancer cells. Indeed, we observed that treatment with zebularine was able 
to alter methylation patterns of a number of genes in PDAC CSCs, including miRNA genes, 
which are regulated by methylation and are known to be involved in a wide range of biologic 
processes, including stem cell differentiation (29). In addition, several miRNAs have been 
shown to be involved in promoting/maintaining stemness in cancers. For example, miR-145 
and miR-9, both well-known tumor suppressors, were found to be suppressed in several 
human cancers (38) due to aberrant DNA methylation of their promoters. Thus, we sought to 
focus our investigation on miRNA genes and to identify specific CpG sites located in the 
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proximity of various miRNA promoter regions, in which zebularine-mediated 
hypomethylation reactivated genes that were originally silenced in CSCs. We observed that 
the miR-17-92 cluster (comprised of six members – miR17, 18a, 19a, 19b, 20a, and 92a) 
was hypermethylated in CSCs versus non-CSCs (Table 1). This finding is in line with recent 
studies from our laboratory showing that the miR-17-92 cluster is consistently 
downregulated in pancreatic CSCs (20). In this study, we showed that gain of function, using 
forced overexpression of miR-17-92, reduced CSC self-renewal capacity, in vivo 
tumorigenicity, and chemoresistance. On the other hand, downregulation of this cluster (i.e., 
inhibition of miR-17-92 using antagomiR) in more differentiated cells had the opposite 
effect, imparting non-CSCs with CSC-like phenotypes. This effect was mediated by 
suppressing multiple members of the NODAL/ACTIVIN/TGFβ1 signaling cascade as well 
as downstream targets, such as P21, P57, and TBX3, all of which have been shown to be 
crucial for maintaining the stem-like state of pancreatic CSCs (11, 20, 39). Our data now 
further validate and expand upon these previous findings and provide novel insights into the 
epigenetic mechanism(s) controlling the suppression of the miR-17-92 cluster in CSCs. We 
show, using different approaches, that reactivation of the miR-17-92 cluster following 
DNMT1 pharmacologic or genetic inhibition augments the phenotype of PDAC CSCs.
Unlike other DNMT inhibitors, zebularine is more stable in aqueous solution and is less 
toxic in vitro and in vivo (40). Continuous exposure of various cancer cell lines to zebularine 
has already been shown to selectively slow tumor cell growth, highlighting its potential 
value as a chemotherapeutic agent. It has previously been shown that zebularine has 
anticancer effects in established PDAC cell lines, supposedly via induction of apoptosis and 
subsequent suppression of tumor growth in vivo (41); however, using primary low-passage 
PDAC cultures derived from equally low-passage PDX tumors, we found no evidence for a 
direct proapoptotic effect. Instead, we show that zebularine treatment forces normally slow-
cycling CSCs into a more proliferative fast-cycling state, which has been previously linked 
to chemosensitization via enhanced expression of miR-17-92 (42). Moreover, we observed a 
marked promotion of CSC differentiation as determined by the loss of "stemness" markers 
(e.g., CD133) and a gain in the expression of differentiation markers including cytokeratin 
and E-cadherin. More importantly, these phenotypes were recapitulated using not only a 
different DNMT inhibitor, decitabine, but also in DNMT1-KO cells, indicating that 
regardless of the approach used, the loss of DNMT1 results in the same phenotypic changes: 
loss of "stemness" and promotion of differentiation.
We would like to highlight that we cannot exclude the possibility that other CSC-inhibitory 
miRNAs could be reactivated by zebularine treatment (or DNMT1 inhibition). Indeed 
Supplementary Table S3 shows that upon treatment with zebularine, β methylation values of 
various miRNA genes were decreased. On the basis of this list and after careful review of the 
literature, we opted to focus on the two miRNAs, miR-203 and miR-205, as both miRNAs 
were previously described to play a role in the biology of pancreatic cancer (43, 44). 
miR-203 acts as a known suppressor of stem cell pluripotent factors; therefore, reactivation 
of miR-203 by hypomethylation might contribute to the reduced levels of pluripotency-
associated genes observed following zebularine treatment in PDAC CSCs. Overexpression 
of miR-203 has also been demonstrated to induce expression of E-cadherin by inhibition of 
the E-cadherin repressors ZEB1/2, which correlates well with our E-cadherin 
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immunofluorescence studies presented herein (45). Thus, the prodifferentiation effect of 
zebularine can also be potentially explained by zebularine-induced hypomethylation of 
miR-203, which has previously been described as an epithelial differentiation factor (19). 
Likewise, miR-205 is a well-known anticancer miRNA and is consistently downregulated in 
clinical pancreatic cancer samples including CSCs (44, 46). miR-205 replenishment reduces 
the expression of the pluripotency/stem cell marker OCT3/4, the CSC marker CD44, and 
resensitizes cells to chemotherapy. On the basis of these findings, we checked the expression 
of miR-203 and miR-205 in PDAC cells treated with zebularine and deficient in DNMT1 
(i.e., DNMT1-KO cells). Although expression of these miRNAs was not significantly 
changed during short-term treatment with zebularine (Supplementary Fig. S6A), we noticed 
a strong and significant increase in DNMT1-KO cells (Supplementary Fig. S6B), suggesting 
that more potent and/or long-term inhibition of DNMT1 is necessary for miR-203 and 
miR-205 reactivation. Collectively, we cannot exclude the possibility that other anti-CSCs 
miR could be reactivated following DNMT1 inhibition; however, our data support the 
hypothesis that reactivation of the miR-17-92 cluster is a dominating driving factor 
responsible for the inhibitory effects observed in the PDAC CSC population.
We are still far from thoroughly understanding the role of DNMT1 in the context of CSC 
biology. Increasing evidence already suggests that DNMT1 protein expression promotes the 
development of PDAC, from normal tissue to precancerous lesions to PDAC (47). Moreover, 
DNMT1 has been demonstrated to be essential for the maintenance of hematopoietic stem 
cells (HSCs)/progenitor cells (48), epidermal progenitor cells and leukemia stem cells (49). 
More recently, DNMT1 was also shown to be indispensable for mammary stem/progenitor 
cells and CSC maintenance, and functional inactivation of this gene drastically reduces 
mammary tumor formation (50). The sum of prior evidence and new insights from our study 
certainly highlight the important role that DNMT1 plays in cancer biology and at the same 
time support the continued development of more effective methylation inhibitors as a means 
of improving the clinical outcome of PDAC patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Pancreatic CSCs bear higher levels of DNA methylation.
A, flow cytometry analysis of autofluorescence in sphere-derived cells from PDAC-185 
SCD (PDAC tumor derived from a single PDAC 185 autofluorescent cell), PDAC-185 
(primary tumor), and PDAC-A6L (PDAC liver metastasis). B, box plots representing DNA 
methylation levels in representative pairs of autofluorescent-negative (Fluo–) and -positive 
(Fluo+) cells from the indicated primary PDAC sphere-derived cultures (*, P < 0.05). C, 
distribution of differently methylated (dm) probes based on their genomic location relative to 
CpG islands (CGI; top). M, methylated. CpG island shores represent regions 0 to 2 kb from 
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CpG islands; shelves indicate regions 2 to 4 kb from CpG islands. Distribution relative to the 
promoter (upstream the transcription start site), and intragenic and intergenic nonpromoter 
regions (bottom). D, quantification of 5mC using the MethylFlash Quantification Kit in non-
CSCs versus CSCs (adherent vs. sphere, Fluo– vs. Fluo+, and CD133– vs. CD133+). adh, 
adherent; sph, spheres. Data are shown as fold change compared with non-CSC (mean ± SD; 
n = 3).
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Figure 2. Pancreatic CSCs overexpress DNMT1.
A, qRT-PCR analysis of DNMT1 mRNA in PDAC adherent (adh) and sphere (sph) cultures. 
Data are normalized to β-actin levels and represent pooled values from different primary 
PDAC cultures (A6L, 185, 354, and 215; *, P < 0.05; n = 5). B, representative Western blot 
images of DNMT1 protein expression in a panel of different primary adherent (adh) and 
sphere (sph)-derived cultures (A6L, 185, and 354) and densitometric quantification (Quant.; 
left). Changes in protein levels are depicted as fold change in pooled adherent cultures 
versus pooled sphere-derived cultures (* P < 0.05; n = 3). C, relative mRNA level of 
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DNMT1 in CSCs (Fluo+ and CD133+) versus non-CSCs (Fluo– and CD133–; *, P < 0.05, n 
= 3; right). D, representative Western blot images of DNMT1 protein expression in CSCs 
(CD133+) versus non-CSCs (CD133–) and densitometric quantification.
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Figure 3. The DNMT1 inhibitor zebularine decreases CSC phenotypes.
A, scheme showing treatment strategy for control (Ctrl) versus zebularine (Zeb) in spheres 
(PDAC-A6L, -185, and -354; left) and Western blot analysis of DNMT1 protein levels 
following treatment (middle). Densitometric quantification analysis (right; *, P < 0.05; n = 
3). B, qRT-PCR analysis of CD133 mRNA in PDAC sphere-derived cultures treated with 
zebularine for 7 days. Data are normalized to β-actin and represented as fold change 
compared with untreated cells (left; *, P < 0.05; n = 3). Representative flow cytometry 
showing the percentage of CD133-positive and -negative cells from PDAC spheres treated 
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for 7 days with zebularine (right). C, number of spheres per mL in first- and second-
generation cultures from primary PDAC tumors (A6L, 185, and 354; *, P < 0.05; n = 4). D, 
qRT-PCR analysis of pluripotency-associated genes in first-generation spheres. Data are 
normalized to β-actin and presented as fold change in comparison with untreated cells (*, P 
< 0.05; n = 4). E, summary of in vivo tumorigenicity of subcutaneously injected control and 
zebularine-treated sphere-derived cells 12 weeks postinjection (left). CSC frequencies 
(Freq.) were determined using the extreme LDA algorithm. Representative flow cytometry 
plots showing the percentage of CD133 expression in digested tumors derived from control 
and zebularine-treated cells (right).
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Figure 4. Knockout of DNMT1 decreases CSC phenotypes.
A, Western blot analysis of DNMT1 protein levels in control (Cas9) and DNMT1-KO cells 
and densitometric quantification (Quant.). B, representative flow cytometry plots of CD133 
cell surface expression in control (Cas9) and DNMT1-KO cells. C, representative images of 
spheres (left) and sphere counts (right) in first- and second-generation in control (Cas9) and 
DNMT1-KO cells (*, P < 0.05; n = 3). D, qRT-PCR analysis of pluripotency-associated 
genes in DNMT1-KO cells. Data are normalized to β-actin and are presented as fold change 
in comparison with control (Cas9) cells (*, P < 0.05; n = 4).
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Figure 5. Zebularine promotes CSC proliferation and differentiation.
A, scheme of the treatment time course (left), Annexin V expression in control (Ctrl) and 
zebularine (Zeb)-treated PDAC-185, PDAC-354, and PDAC-A6L (n = 3; middle). Annexin 
V expression determined within the CD133+ and CD133− fractions, using CD133-PE for 
zebularine and control-treated PDAC-185, PDAC-354, and PDAC-A6L cultures (right). B, 
representative flow cytometry plots for Ki-67 staining in control versus zebularine-treated 
PDAC-354 cultures (left) and combined quantification (right; *, P < 0.05; n = 6). C, 
quantification of flow cytometry analysis of CD133 expression in control versus zebularine-
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treated spheres from PDAC-185 and PDAC-A6L (*, P < 0.05; n = 3). D, quantification of 
the mean fluorescence intensity (MFI) of pan-cytokeratin (pan-CK) staining in control 
versus zebularine-treated primary PDAC cultures (left; * P, < 0.05; n = 8). Representative 
confocal images are shown (right). E, representative confocal images of E-cadherin staining 
for control versus zebularine-treated cultures.
Zagorac et al. Page 23
Cancer Res. Author manuscript; available in PMC 2017 February 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 6. The effect of zebularine is mediated via hypomethylation of the miR-17-92 cluster.
A, box plots representing the decrease in DNA methylation levels in pooled control versus 
zebularine-treated PDAC cultures. *, P < 0.05. B, qRT-PCR analysis of members of the 
miR-17-92 cluster (miR17, 18a, 19a, 19b, 20a) in PDAC-A6L and PDAC-185 sphere-
derived cultures (*, P < 0.05; n = 4). C, qRT-PCR analysis of miR-17-92 target genes in 
PDAC-A6L and PDAC-185 sphere-derived cultures. Data are normalized to β-actin levels 
and are represented as fold change compared with untreated cells (*, P < 0.05; n = 3). D, 
Western blot analysis of P21 protein levels in control versus zebularine-treated cultures (top) 
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and subsequent densitometric quantification (bottom). Changes in protein levels are 
represented as fold change compared with untreated cells. E, qRT-PCR analysis for MYC 
expression in PDAC-185 cells. Data are normalized to β-actin and are represented as fold 
change in comparison with untreated cells (*, P < 0.05; n = 4). F, PDAC adherent cells were 
treated with antagomiR (Ant) for miR-17, 18a, 19a/b, and 20a for 24 hours. Cells were 
plated for sphere formation assay, treated with zebularine for 7 days, and number of 
spheres/mL were determined (*, P < 0.05; n = 6).
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Table 1
Hypermethylated miRs in CSC-enriched spheres
has-miRNA FC_sph vs. adh
hsa-miR548N 1.45
hsa-miR1281 1.42
hsa-miR1259 1.41
hsa-miR1225 1.40
hsa-miR130B/hsa-miR301B 1.40
hsa-miR17HG 1.34
hsa-miR1224 1.31
hsa-miR22 1.26
hsa-miR1227 1.26
hsa-miR1226 1.25
hsa-miR330 1.24
hsa-miR135B 1.24
hsa-miR585 1.21
hsa-miR600 1.21
hsa-miR375 1.20
NOTE: Given is the fold change (FC) of β-methylation values for spheres versus adherent. Only data for FC ≥ 1.20 are shown.
Abbreviations: adh, adherent; sph, spheres.
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